Vascular Biogenics Ltd. (NASDAQ:VBLT) was the recipient of unusually large options trading activity on Tuesday. Stock traders purchased 898 call options on the stock. This represents an increase of approximately 1,097% compared to the typical volume of 75 call options.
A hedge fund recently bought a new stake in Vascular Biogenics stock. Zurcher Kantonalbank Zurich Cantonalbank bought a new position in Vascular Biogenics Ltd. (NASDAQ:VBLT) in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The firm bought 22,100 shares of the biopharmaceutical company’s stock, valued at approximately $135,000. Zurcher Kantonalbank Zurich Cantonalbank owned about 0.08% of Vascular Biogenics at the end of the most recent quarter. Institutional investors own 6.59% of the company’s stock.
Shares of Vascular Biogenics (VBLT) opened at $7.95 on Friday. The stock has a market cap of $227.72, a PE ratio of -10.06 and a beta of -3.00. Vascular Biogenics has a twelve month low of $3.90 and a twelve month high of $9.05.
COPYRIGHT VIOLATION NOTICE: “Vascular Biogenics Target of Unusually High Options Trading (VBLT)” was originally posted by Community Financial News and is the property of of Community Financial News. If you are reading this report on another domain, it was copied illegally and republished in violation of US and international copyright & trademark legislation. The legal version of this report can be accessed at https://www.com-unik.info/2018/01/07/vascular-biogenics-target-of-unusually-high-options-trading-vblt.html.
About Vascular Biogenics
Vascular Biogenics Ltd. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of treatments for cancer. The Company’s program is based on its Vascular Targeting System (VTS) platform technology, which utilizes genetically targeted therapy to destroy newly formed, or angiogenic, blood vessels.
Receive News & Ratings for Vascular Biogenics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vascular Biogenics and related companies with MarketBeat.com's FREE daily email newsletter.